Q4 2025 Management View Michael Mahoney, Chairman, President & CEO, stated, "In 2025, we achieved over $20 billion in sales ...

New stroke risk reduction therapy with thromboresistant coating is designed to advance procedural performance and safety MARLBOROUGH, Mass., Sept. 6, 2023 /PRNewswire/ -- Boston Scientific Corporation ...

Boston Scientific recently reported past third-quarter 2025 results that surpassed expectations on both adjusted earnings per share and revenue, while raising its full-year 2025 EPS guidance and ...

17 deaths and 120 serious injuries have been reported due to complications during Watchman procedures. Boston Scientific warned Watchman customers of a higher risk of complications during procedures ...